Drug Profile
CLX 0101
Latest Information Update: 25 Oct 2005
Price :
$50
*
At a glance
- Originator Calyx Therapeutics (CEASED)
- Class Amino acids; Antihyperglycaemics; Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 25 Oct 2005 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
- 29 Jan 2003 CLX 0101 is available for licensing (http://www.calyxti.com)
- 29 Jan 2003 Suspended - Preclinical for Type-2 diabetes mellitus in USA (PO)